Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Oncology

Novartis Posts Q3 Sales Rise but Misses Views, Reaffirms 2025 Outlook

Investors focused on U.S. generic erosion of Entresto that pressured growth.

Genmab to Buy Merus for $8 Billion to Secure Petosemtamab Cancer Drug

Merck Launches $3 Billion Cost-Optimization Program Following Q2 Revenue Miss